How the FX Laser is Influencing Medicine

Tuesday, June 15th | 2:00-3:00pm EST
with Erchonia’s
President – Steven Shanks & Clinical Affairs Manager – Travis Sammons

We made history in 2019 when the FDA awarded Erchonia market clearance as the 1st & ONLY non-invasive device market cleared for Overall Nociceptive Musculoskeletal Pain.  The Erchonia Research Team will walk you through the rigorous FDA research process, clinical results and our continued dedication to research.  The experts review the proven mechanisms and biomarkers that contribute to the reduction of pain & inflammation.  The webinar finale will be a groundbreaking discussion of what is on the horizon for laser medicine!

Webinar Topics:

  • Diligent Research Progression to Becoming the Only FDA Market Cleared Laser for Overall Nociceptive Musculoskeletal Pain
  • NEW Published Data from Double-Blind, Placebo Controlled Trial involving over 400 Subjects
  • FDA 510(k)s:  Non-Thermal Lasers vs. FDA Exempt i.e. lasers for topical heating
  • Photochemical vs. Photothermal


About Erchonia
Erchonia Corporation was founded in 1996 as a small family business, and even though we’ve grown into an international enterprise, we still operate under the founding principles that guided us to our present success. Our commitment to the legitimate advancement of low-level laser therapy (3LT®) through scientific and clinical research has transformed Erchonia into a world leader in the field of LLLT technology. The integrity, diligence, quality and commitment of our company are evident in the rigorous process we follow in order to take a research hypothesis from concept to viable, agency-approved product and treatment method. To ensure a steadfast adherence to our unique all-encompassing approach, our company serves as manufacturer, marketer, developer, promoter, creator and user of all our products.

Last Updated on June 11, 2021 by Erchonia